Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
A company as rare as the diseaseswe focus on.
Few companies focus exclusively on endocrine diseases. We do. Many patients have longed for better therapies that offer symptom improvement and a better quality of life. We’re innovating to try to make this happen. Bringing cutting-edge science to underserved patients is important work. We do it every day.
We've built a better workplace to help patients build better lives.
“Focused intensity” is how we like to describe our approach to our jobs. There’s a lot of work to do when you’re trying to improve patients’ lives. Lots of discoveries to make. Lots of goals to meet. But we love the challenges and embrace them head-on. Intrigued?
Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)
Crinetics Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly
A company as rare as the diseaseswe focus on.
Few companies focus exclusively on endocrine diseases. We do. Many patients have longed for better therapies that offer symptom improvement and a better quality of life. We’re innovating to try to make this happen. Bringing cutting-edge science to underserved patients is important work. We do it every day.
We've built a better workplace to help patients build better lives.
“Focused intensity” is how we like to describe our approach to our jobs. There’s a lot of work to do when you’re trying to improve patients’ lives. Lots of discoveries to make. Lots of goals to meet. But we love the challenges and embrace them head-on. Intrigued?